Get started
Author

Valentina Giunchi

Observed names: Giunchi Valentina, Giunchi, V, Giunchi, Valentina
ORCID: 0000-0001-5841-8520
Observed ORCID: 0000-0001-5841-8520
OpenAlex ID: A5084631806
Challenges and Opportunities in Accessing and Analysing FAERS Data: A Call Towards a Collaborative Approach
2023 · Valentina Giunchi, Michele Fusaroli, et al. · Drug Safety · 56
PDF
Call to action: Pharmaceutical residues in the environment: threats to ecosystems and human health
2024 · Carlotta Lunghi, Maria Rosa Valetto, et al. · Drug Safety · 47
PDF
Enhancing Transparency in Defining Studied Drugs: The Open-Source Living DiAna Dictionary for Standardizing Drug Names in the FAERS
2024 · Michele Fusaroli, Valentina Giunchi, et al. · Drug Safety · 41
Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System
2022 · Michele Fusaroli, Emanuel Raschi, et al. · The International Journal of Neuropsychopharmacology · 41
PDF
Exploring the underlying mechanisms of drug‐induced impulse control disorders: a pharmacovigilance‐pharmacodynamic study
2022 · Michele Fusaroli, Valentina Giunchi, et al. · Psychiatry and Clinical Neurosciences · 33
PDF
Reporting of late-onset immune-related adverse events with immune checkpoint inhibitors in VigiBase
2024 · Roberta Noseda, Francesca Bedussi, et al. · Journal for ImmunoTherapy of Cancer · 30
PDF
Unveiling the Burden of Drug-Induced Impulsivity: A Network Analysis of the FDA Adverse Event Reporting System
2024 · Michele Fusaroli, Stefano Polizzi, et al. · Drug Safety · 23
Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System
2022 · Emanuel Raschi, Michele Fusaroli, et al. · Cancers · 22
PDF
Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System
2023 · Michele Fusaroli, Guido Pelletti, et al. · Drug Safety · 21
PDF
Strategies and Tools for Supporting the Appropriateness of Drug Use in Older People
2022 · Carlotta Lunghi, Caterina Trevisan, et al. · Pharmaceuticals · 21
PDF
The environmental impact of pharmaceuticals in Italy: Integrating healthcare and eco‐toxicological data to assess and potentially mitigate their diffusion to water supplies
2023 · Valentina Giunchi, Michele Fusaroli, et al. · British Journal of Clinical Pharmacology · 17
Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors
2023 · Monia Sisi, Giovanni Vitale, et al. · JTO Clinical and Research Reports · 14
PDF
Environmental sustainability—an essential component of rational use of medicines
2024 · Valentina Giunchi, Michele Fusaroli, et al. · International Journal of Pharmacy Practice · 13
Attitudes, barriers, and facilitators toward tools supporting appropriate prescribing among healthcare professionals: a cross-sectional study
2025 · Monia Donati, Valentina Giunchi, et al. · European Journal of Clinical Pharmacology · 7
PDF
Assessing the environmental impact of medicines in Italy using data from the Italian Medicines Agency
2025 · Valentina Giunchi, Michele Fusaroli, et al. · British Journal of Clinical Pharmacology · 7
Characterizing post-mortem blood concentrations in methadone-related deaths
2025 · Guido Pelletti, Valentina Giunchi, et al. · International Journal of Legal Medicine · 5
PDF
A collection of Predicted No-Effect Concentrations of human pharmaceuticals and their metabolites
2023 · Valentina Giunchi, Elisabetta Poluzzi · bioRxiv (Cold Spring Harbor Laboratory) · 3
PDF
Authors’ Reply to Cappello et al. Comment on: “Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System”
2023 · Michele Fusaroli, Guido Pelletti, et al. · Drug Safety · 3
Treatment sequences in moderate-to-severe psoriasis: a hospital-based retrospective analysis
2025 · Angela Boccia, Valentina Giunchi, et al. · Expert Opinion on Biological Therapy · 2
PDF
A pharmacological view on accounting for pharmacokinetic factors in the estimation of pharmaceutical emissions based on drug usage data
2025 · Frank Klont, J. Stein Bellinga, et al. · Environment International · 2
Posterior Reversible Encephalopathy Syndrome with Angiogenesis Inhibitors for Solid Tumours: Clues from a Disproportionality Analysis of the FDA Adverse Event Reporting System and Pharmacodynamics
2026 · Monia Donati, Chiara Cancellerini, et al. · Targeted Oncology · 1
PDF
Neutropenia and infectious events during off-label treatment with venetoclax in children with malignant disease: a pharmacovigilance analysis of FDA adverse event reporting system reports
2026 · Edoardo Muratore, Valentina Giunchi, et al. · Annals of Hematology · 1
PDF
Comparing Existing Algorithms for Retrieving Pregnancy-related Adverse Event Reports
2026 · Sara Hedfors Vidlin, Valentina Giunchi, et al. · medRxiv · 1
PDF
Infections-related Safety Profile of Efgartigimod Alpha and Immunoglobulins in Myasthenia Gravis (S34.003)
2025 · Valentina Giunchi, Michele Fusaroli, et al. · Neurology · 1
The environmental impact of pharmaceuticals: an evidence-mapping review of recent data on aquatic concentrations and predictable effects
2024 · Renda Francesca, Giunchi Valentina, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 1
PDF
Works count: 40
Citation count: 420
H-index: 13
I10-index: 13
Year
Topic
Type